ATF4 and Parkinson disease: Adaptaquin (AQ), a hydroxyquinoline-based inhibitor of PHDs, abrogates ATF4-CHOP-dependent neuronal death and improves functional outcomes in mouse models of ICH and Parkinson’s disease [15, 19].